AU2003267169A1 - Compounds, compositions and methods - Google Patents

Compounds, compositions and methods

Info

Publication number
AU2003267169A1
AU2003267169A1 AU2003267169A AU2003267169A AU2003267169A1 AU 2003267169 A1 AU2003267169 A1 AU 2003267169A1 AU 2003267169 A AU2003267169 A AU 2003267169A AU 2003267169 A AU2003267169 A AU 2003267169A AU 2003267169 A1 AU2003267169 A1 AU 2003267169A1
Authority
AU
Australia
Prior art keywords
compositions
compounds
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003267169A
Other languages
English (en)
Other versions
AU2003267169A8 (en
Inventor
Andrew Mcdonald
Han-Jie Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytokinetics Inc
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of AU2003267169A8 publication Critical patent/AU2003267169A8/xx
Publication of AU2003267169A1 publication Critical patent/AU2003267169A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
AU2003267169A 2002-09-13 2003-09-11 Compounds, compositions and methods Abandoned AU2003267169A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41074302P 2002-09-13 2002-09-13
US60/410,743 2002-09-13
PCT/US2003/028696 WO2004024086A2 (en) 2002-09-13 2003-09-11 Compounds, compositions and methods

Publications (2)

Publication Number Publication Date
AU2003267169A8 AU2003267169A8 (en) 2004-04-30
AU2003267169A1 true AU2003267169A1 (en) 2004-04-30

Family

ID=31994196

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003267169A Abandoned AU2003267169A1 (en) 2002-09-13 2003-09-11 Compounds, compositions and methods

Country Status (5)

Country Link
US (1) US20080312310A1 (cg-RX-API-DMAC7.html)
EP (1) EP1554265A4 (cg-RX-API-DMAC7.html)
JP (1) JP2005539062A (cg-RX-API-DMAC7.html)
AU (1) AU2003267169A1 (cg-RX-API-DMAC7.html)
WO (1) WO2004024086A2 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4664597B2 (ja) 2002-04-17 2011-04-06 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
DE602005008953D1 (de) 2004-05-21 2008-09-25 Novartis Vaccines & Diagnostic Substituierte chinolinderivate als inhibitoren von mitotischem kinesin
MXPA06014909A (es) 2004-06-18 2007-02-28 Chiron Corp Derivados de n-(1-(1-bencil -4-fenil-1h -imidazol -2-il)-2, 2-dimetilpropil) benzamida y compuestos relacionados como inhibidores de proteina de huso de cinesina (ksp) para el tratamiento del cancer.
CN101027309B (zh) 2004-08-18 2010-10-27 阿斯利康(瑞典)有限公司 所选择的稠合嘧啶酮的对映体和在治疗和预防癌症中的用途
EP1807399A2 (en) 2004-10-19 2007-07-18 Novartis Vaccines and Diagnostics, Inc. Indole and benzimidazole derivatives
MX2009005071A (es) 2006-11-13 2009-05-25 Novartis Ag Compuestos de pirazol y triazol sustituidos como inhibidores de ksp.
GEP20125415B (en) 2007-01-05 2012-03-12 Novartis Ag Imidazole derivatives as kinesin spindle protein inhibitors (eg-5)
US8912244B2 (en) * 2012-03-09 2014-12-16 Protocol Environmental Solutions Inc. Non-film forming compositions and methods of protecting cured concrete and cementitious materials

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3177130D1 (de) * 1980-08-30 1990-01-11 Hoechst Ag Aminosaeurederivate, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung.
US4434296A (en) * 1982-05-17 1984-02-28 The Upjohn Company Process for preparing intermediates for antiatherosclerotic compounds
US4482558A (en) * 1982-06-18 1984-11-13 Pfizer Inc. Antifungal amide and urea derivatives of (3-amino-2-aryl-2-hydroxyprop-1-yl)-1H-1,2,4-triazoles
JPS62201882A (ja) * 1985-11-18 1987-09-05 Yamanouchi Pharmaceut Co Ltd イソフラボン誘導体
IN164232B (cg-RX-API-DMAC7.html) * 1986-04-11 1989-02-04 Hoechst India
IL85554A0 (en) * 1987-03-02 1988-08-31 Takeda Chemical Industries Ltd Chromone derivatives
JPH0753725B2 (ja) * 1987-10-08 1995-06-07 富山化学工業株式会社 4h―1―ベンゾピラン―4―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤
USH1427H (en) * 1988-04-06 1995-04-04 Briet; Phillipe Substituted flavonoid compounds, their salts, their manufacture and their use in combination with interleukin-2
US5304548A (en) * 1988-08-16 1994-04-19 The Upjohn Company Bivalent ligands effective for blocking ACAT enzyme for lowering plasma triglycerides and for elevating HDL cholesterol
US5180717A (en) * 1988-08-16 1993-01-19 The Upjohn Company Bivalent ligands effective for blocking ACAT enzyme for lowering plasma triglycerides and for elevating HDL cholesterol
US5284856A (en) * 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
US5703075A (en) * 1988-12-21 1997-12-30 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
US5082849A (en) * 1989-07-13 1992-01-21 Huang Fu Chich Quinolinyl-benzopyran derivatives as antagonists of leukotriene D4
US4977162A (en) * 1989-07-13 1990-12-11 Rorer Pharmaceutical Corporation Quinolinyl-chromone derivatives and use for treatment of hypersensitive ailments
US5215989A (en) * 1989-12-08 1993-06-01 Merck & Co., Inc. Nitrogen-containing heterocyclic compounds as class III antiarrhythmic agents
US5032598A (en) * 1989-12-08 1991-07-16 Merck & Co., Inc. Nitrogens containing heterocyclic compounds as class III antiarrhythmic agents
CA2087423A1 (en) * 1990-07-25 1992-01-26 Tatsuki Shiota Benzopyran derivative, process for producing the same and pharmaceutical composition containing the same
US5605896A (en) * 1992-02-25 1997-02-25 Recordati S.A., Chemical And Pharmaceutical Company Bicyclic heterocyclic derivatives having α1 adrenergic and 5HT1A activities
CA2184002A1 (en) * 1994-02-23 1995-08-31 Jeffrey M. Blaney Method and compositions for increasing the serum half-life of pharmacologically active agents
EP0764159B1 (en) * 1994-06-10 2000-08-09 Smithkline Beecham Plc C -4 amide substituted compounds and their use as therapeutic agents
US5607928A (en) * 1994-08-05 1997-03-04 Zeneca Limited Carbapenem derivatives containing a bicyclic ketone substituent and their use as anti-infectives
US5602171A (en) * 1995-06-07 1997-02-11 Sugen Inc. Methods of inhibiting phosphatase activity and treatment of disorders associated therewith using naphthopyrones and derivatives thereof
US6087385A (en) * 1998-10-30 2000-07-11 University Of Mississippi Flavonoid derivatives
US6028088A (en) * 1998-10-30 2000-02-22 The University Of Mississippi Flavonoid derivatives
DE19858341A1 (de) * 1998-12-17 2000-06-21 Merck Patent Gmbh Chromanderivate
US6559160B1 (en) * 1999-08-27 2003-05-06 Chemocentryx, Inc. Compounds and methods for modulating cxcr3 function
GB9920912D0 (en) * 1999-09-03 1999-11-10 Indena Spa Novel derivatives of flavones,xanthones and coumarins
DE60017157T2 (de) * 1999-09-16 2005-12-22 Curis, Inc., Cambridge Vermittler von igel signalwegen, deren zusammenstellungen und verwendungen
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US6559145B2 (en) * 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6903121B1 (en) * 2000-08-17 2005-06-07 Allergan, Inc. Treatment of tumors with acetylenes disubstituted with a phenyl or heteroaromatic group and a substituted chromanyl, thiochromanyl or tetrahydroquinolinyl group in combination with other anti-tumor agents
NZ526622A (en) * 2000-12-11 2006-07-28 Amgen Sf Llc CXCR3 antagonists
JP2003286301A (ja) * 2002-01-22 2003-10-10 Omron Corp 2段階硬化型樹脂組成物、微細賦形成形物およびその製造方法、ならびに精密機器
JP4664597B2 (ja) * 2002-04-17 2011-04-06 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
ATE423110T1 (de) * 2002-07-17 2009-03-15 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
AU2003249534A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc 6,6-fused heteroaryl derivatives as matrix metalloproteinase inhibitors
JP2007507539A (ja) * 2003-10-06 2007-03-29 サイトキネティクス・インコーポレーテッド 化合物、組成物及び方法
WO2005040163A1 (en) * 2003-10-28 2005-05-06 Dr. Reddy's Laboratories Ltd Heterocyclic compounds that block the effects of advanced glycation end products (age)

Also Published As

Publication number Publication date
EP1554265A2 (en) 2005-07-20
WO2004024086A2 (en) 2004-03-25
JP2005539062A (ja) 2005-12-22
AU2003267169A8 (en) 2004-04-30
US20080312310A1 (en) 2008-12-18
WO2004024086A3 (en) 2004-07-22
EP1554265A4 (en) 2008-05-07

Similar Documents

Publication Publication Date Title
AU2003262747A1 (en) Compounds, compositions, and methods
AU2003236527A1 (en) Compounds, compositions, and methods
AU2003265242A1 (en) Compounds, compositions, and methods
AU2003270015A1 (en) Compounds, compositions, and methods
AU2003299612A1 (en) Compounds, compositions and methods
EP1503993A4 (en) COMPOUNDS, METHODS AND COMPOSITIONS
EP1542699A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
AU2003285288A1 (en) Composition
IL164581A0 (en) Compounds, compositions and methods
AU2003277079A1 (en) Compounds, compositions, and methods
AU2003256805A1 (en) Compounds compositions and methods
AU2002950744A0 (en) Composition
AU2003235708A1 (en) Polytartrate composition
AU2003290507A1 (en) Compounds, compositions and methods
IL167936A0 (en) Compounds, compositions,and methods
AU2003208411A1 (en) Anti-glycolytic composition
AU2003269904A1 (en) Antigen-polymer compositions
AU2003300031A1 (en) Compounds, compositions, and methods
AU2002953252A0 (en) Compositions, Compounds and Methods for their Preparation
AU2003267169A8 (en) Compounds, compositions and methods
AU2003208841A1 (en) Gasolinen compositions
AU2003268772A1 (en) Oil-barrier composition
AU2003216382A1 (en) Idothyronine compositions
AU2003218497A1 (en) FACTORVIIa COMPOSITIONS
HK1074572A (en) Compounds, compositions, and methods

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase